159 results on '"Yeung, Tsz-Lun"'
Search Results
2. Abstract A094: CAF-derived MFAP5 enhances immune escape through up-regulating immune checkpoint mediator CD47 in ovarian cancer cells and CD8+ T cells
3. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature
4. ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment
5. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth
6. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance
7. Supplementary Figure 4 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
8. Supplementary Data from Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer
9. Supplementary Figure 3 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
10. Supplementary Table 1 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
11. Supplementary Table 2 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
12. Supplementary Table 3 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
13. Supplementary Figure 2 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
14. Data from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
15. Supplementary Figure Legend from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
16. Supplementary Figure 1 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
17. Supplementary Figure 4 from TGF-β Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment
18. Supplementary Table 1 from TGF-β Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment
19. Supplementary Figure 3 from TGF-β Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment
20. Figures and Tables Legends from TGF-β Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment
21. Supplementary Figure 1 from TGF-β Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment
22. Supplementary Table 2 from TGF-β Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment
23. Data from TGF-β Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment
24. Supplementary Experimental Procedures from TGF-β Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment
25. Supplementary Figure 5 from TGF-β Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment
26. Supplementary Table 3 from TGF-β Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment
27. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
28. Additional file 2 of Ryanodine receptor 1-mediated Ca2+ signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes
29. Additional file 1 of Ryanodine receptor 1-mediated Ca2+ signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes
30. 609 Combining bintrafusp alfa with abituzumab enhances suppression of the TGF-β signaling pathway
31. Ryanodine Receptor 1-mediated Ca2+ signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes
32. Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion
33. Abstract 443: Bintrafusp alfa enhances the antitumor efficacy of anti-VEGF and VEGF receptor kinase inhibitors in preclinical solid tumor models
34. Ryanodine receptor 1-mediated Ca2+ signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes.
35. SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment
36. Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436
37. Deep learning on image-omics data in identifying prognostic immune biomarkers for ovarian cancer
38. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype
39. Abstract 854: An artificial intelligence pipeline for imaging mass cytometry data analysis and its application in ovarian cancer prognostic biomarker discovery
40. Abstract 2232: A novel immune checkpoint regulator in the ovarian cancer microenvironment
41. Abstract 1573: Association between TGF-β signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer
42. Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression
43. Abstract C099: Anticancer immunotherapy by MFAP5 blockade inhibits fibrosis and enhances chemosensitivity in ovarian and pancreatic cancer
44. Abstract B045: A novel immune checkpoint regulator in the ovarian cancer microenvironment
45. Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer
46. Transcriptional regulation of IER3IP1 gene by tumor necrosis factor-α and Sp family proteins
47. Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers
48. Abstract 3370: Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers
49. An image informatics pipeline for imaging mass cytometry to characterize the immune landscape in pre- and on-treatment immune therapy and its application in recurrent platinium-resistant epithelial ovarian cancer
50. ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.